ABSTRACT
Aortic stenosis (AS) is a heterogeneous disease of aging characterized by valvular calcification and distinct structural, electrical, and hemodynamic remodeling that are incompletely captured by any single diagnostic measure. Here we show that three AI-derived digital biomarkers resolve AS-related remodeling into complementary structural (cine-CMR Digital AS Severity Index, DASSi), electrical (AI-ECG), and hemodynamic (phase-contrast CMR peak aortic velocity) axes. Among 68,714 UK Biobank participants, all three biomarkers were independently associated with prevalent AS and prospectively predicted aortic valve replacement. Genetic and transcriptomic analyses of the digital phenotypes revealed partially distinct, heritable architectures: peak aortic velocity aligned closely with clinical AS genetics, whereas DASSi and AI-ECG defined a shared myocardial-remodeling axis largely independent of clinical AS susceptibility. These findings support AS as a multidimensional remodeling syndrome and establish a novel digital phenotyping framework for dissecting complex cardiovascular disease into complementary, biologically informative axes.
Competing Interest Statement
E.K.O. acknowledges research support from the American Heart Association (AHA, award no. 26CDA1612298), the Robert A. Winn Excellence in Clinical Trials Career Development Award, the Wiesman Award for Excellence in Early-Career ATTR Research, the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine (P30AG021342) through a Pepper Scholar award, and the Yale Center for Clinical Investigation (YCCI) through a KL2 award through a CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). He is a named co-inventor on patent applications (filed through Yale University) and granted patents licensed through the University of Oxford to Caristo Diagnostics Ltd, outside the scope of this work. He is a co-founder of Evidence2Health LLC, and has previously consulted for Caristo Diagnostics Ltd and Ensight-AI Inc. He has also received honoraria from Clinical Education Alliance, and serves as an Associate Editor for the European Heart Journal. R.K. acknowledges support from the National Heart, Lung And Blood Institute (R01HL167858 and K23HL153775) and the National Institute on Aging (under award number R01AG089981) of the National Institutes of Health. He is an Associate Editor of JAMA and receives research support, through Yale, from the Blavatnik Foundation, Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of Pending Patent Applications WO2023230345A1, US20220336048A1, 63/346,610, 63/484,426, 63/508,315, 63/580,137, 63/606,203, 63/619,241, and 63/562,335, and a co-founder of Ensight-AI, Inc and Evidence2Health, LLC. P.M.C. is a founder and shareholder of ACE Health and Ensight-AI. The remaining authors have nothing to disclose. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official views of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Yale University School of Medicine Institutional Review Board approved this study and waived the requirement for informed consent. This research was conducted using the UK Biobank Resource under application number #71033.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The underlying data were accessed through an approved application to the UK Biobank (#71033). Following an application to the UK Biobank committee, our team was granted a waiver to export imaging and ECG data into a secure Yale university-managed server to enable inference using our deep learning-enabled algorithms. The summary GWAS statistics for our quantitative metrics, namely peak aortic velocity, DASSi and AI-ECG score of AS will be made available on Zenodo upon publication.
Funder Information Declared
